North American electroceuticals market is expected to grow at a CAGR of 7.0% during the forecast period. The market growth in North America can be attributed to the rising geriatric population, frequent US FDA approvals for innovative electroceutical devices, and growing adoption of minimally invasive/non-invasive surgeries for treatment of several diseases owing to growing awareness among patients related to electroceuticals. Furthermore, according to the Heart & Stroke Foundation in Canada, 1.6 million fatalities occur every year due to stroke and at least 1.3 million Canadians live with heart disease. Moreover, the rate of adoption of advanced techniques is the highest in North America. This fact is further supporting the growth of electroceuticals market in North America.
To Request a Sample of our Report on North American Electroceuticals Market: https://www.omrglobal.com/request-sample/north-american-electroceuticals-market
The market is segmented on the basis of product and end-user. On the basis of product, the market is segmented into cardioverter defibrillators and cardiac pacemaker, deep brain stimulators (DBS), spinal cord stimulators (SCS), vagus nerve stimulators, hearing aids, and cochlear implants, and others such as sacral nerve stimulators, and transcutaneous electrical nerve stimulators. By End-user segment, the market is segmented into hospitals & clinics and homecare and other. Few players operating in the North American electroceuticals market include Medtronic PLC, Abbott Laboratories Inc., Boston Scientific Corp., LivaNova PLC, Cochlear, Ltd., Sonova Holding AG, Nevro Corp., ElectroCore LLC, and BioElectronics Corp.
(Get 15% Discount on Buying this Report)
A full Report of North American Electroceuticals Market is Available at: https://www.omrglobal.com/industry-reports/north-american-electroceuticals-market
North American Electroceuticals Market Segmentation
By Product and its Application
· Cardioverter Defibrillators and Cardiac Pacemaker
· Arrhythmias
· Deep Brain Stimulators
· Parkinson’s Disease
· Depression
· Spinal Cord Stimulators
· Failed Back Syndrome
· Ischemia
· Vagus Nerve Stimulators
· Epilepsy
· Cochlear Implants
· Sensorineural Hearing Loss
· Others (Sacral Nerve Stimulators, Transcutaneous Electrical Nerve Stimulators)
· Urinary Incontinence
· Treatment-Resistant Depression
By End-User
· Hospitals and Clinics
· Homecare and Other
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
